A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Public ClinicalTrials.gov record NCT03395704. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-Center, Randomized, Placebo Controlled, Single-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Study identification
- NCT ID
- NCT03395704
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- La Jolla Pharmaceutical Company
- Industry
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Interventions
- LJPC-401 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 28, 2017
- Primary completion
- Oct 27, 2019
- Completion
- Oct 27, 2019
- Last update posted
- Jun 8, 2022
2017 – 2019
United States locations
- U.S. sites
- 18
- U.S. states
- 9
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | North Little Rock | Arkansas | 72117 | — |
| Investigative Site | Los Angeles | California | 90036 | — |
| Investigative Site | Palo Alto | California | 94305 | — |
| Investigative Site | Rialto | California | 92377 | — |
| Investigational Site | San Diego | California | 91942 | — |
| Investigative Site | San Francisco | California | 94115 | — |
| Investigative Site | Jacksonville | Florida | 32204 | — |
| Investigative Site | Indianapolis | Indiana | 46202 | — |
| Investigative Site | Wyoming | Michigan | 49519 | — |
| Investigative Site | Jackson | Mississippi | 39216 | — |
| Investigative Site | East Setauket | New York | 11733 | — |
| Investigative Site | Manhasset | New York | 11030 | — |
| Investigative Site | New York | New York | 10029 | — |
| Investigative Site | Dallas | Texas | 75246 | — |
| Investigative Site | Fort Worth | Texas | 76104 | — |
| Investigative Site | Houston | Texas | 77058 | — |
| Investigative Site | San Antonio | Texas | 78215 | — |
| Investigative Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03395704, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03395704 live on ClinicalTrials.gov.